Marvell与Lumentum全股票交易面临监管审查与中国SAMR的不确定性
Marvell与Lumentum全股票交易面临监管审查与中国SAMR的不确定性
Conclusion: No regulator has publicly challenged the Marvell–Lumentum deal in the sources I could find, so a block is not the base case. The more likely path is a long review ending in conditional clearance, with China's SAMR as the main source of delay. The market is pricing real doubt: merger-arbitrage pros put the odds of closing at about 50%, and LITE trades about 18% below the value implied by the exchange ratio. The regulatory fee structure shows both parties treated a regulatory failure as a real possibility.
Data as of: Quotes are the Nov 13, 2026 close (16:00 ET, Friday). Deal and regulatory news runs through Nov 10–12, 2026. I found no filing or report after Nov 12 confirming HSR filing status, a second request, or SAMR acceptance.
What is known about the deal
- Marvell (MRVL) agreed on Nov 2, 2026 to acquire Lumentum (LITE) in an all-stock deal. The fixed ratio is 4.5 MRVL shares per LITE share, and at announcement, a to the Oct 28 unaffected close. Marvell holders would own about 67% of the combined company. [Source: Marvell press release, Nov 2]
- Closing requires both shareholder votes, HSR expiry, "certain other required regulatory approvals," and no legal restraint. The companies expect closing in the first half of 2028. [Source: Lumentum 8-K, Nov 2]
- Outside date is Nov 1, 2027, extendable to Feb 1, May 1 and Aug 1, 2028 if required regulatory approvals are still outstanding. [Source: Lumentum 8-K]
- Marvell controls the regulatory strategy after consulting Lumentum. Marvell need not accept a remedy that is materially adverse to the combined business. [Source: Driven research note on the 8-K terms]
Termination economics (from the merger agreement)
- Marvell pays a $3.2 billion regulatory termination fee if the deal fails on the outside date, under a final HSR or other antitrust legal restraint, or after a final regulatory denial. This applies only if all non-regulatory conditions are satisfied or capable of being satisfied at closing.
- Lumentum pays a fee in corresponding shareholder-side cases. Marvell pays in alternative-deal cases.
- The regulatory fee equals of the implied EV. [Calculation]
Regulatory picture
- Bloomberg Intelligence analyst Jennifer Rie expects approvals, likely with remedies, but called China a "wild card" and named China's merger watchdog as the main timing question. [Source: Briefs, Nov 10]
- Concern centres on overlap between Marvell's DSP/signal-processing products and Lumentum's laser and optical-module business. Commentary from Counterpoint and TrendForce expects reviewers to focus on laser access, bundling, and Lumentum's own module unit. These are secondary analyses, not regulator statements. [Source: Driven research note; Global Business Digest; Counterpoint]
- The 8-K does not name China as a required approval. One legal analysis cited by secondary press says the full list sits in an unpublished disclosure letter. [Source: Driven research note] This is unverified.
- Precedents cited by press: Qualcomm/NXP (2018) was abandoned; Intel/Tower (2023) was ended without Beijing's approval; Broadcom/VMware received conditional approval after months of limbo. Marvell's Cavium and Inphi purchases cleared China in about eight and five months, according to a Rosenblatt report cited by Briefs. [Source: Briefs, Nov 10]
- Statutory SAMR clocks (30/90/60 days) start only on formal acceptance and can be paused, so real timelines can run well beyond them. [Source: Driven research note, citing Dombey Capital; secondary]
Factors that will determine the outcome
- SAMR and remedies. Whether China demands supply commitments, third-party access, or limits on bundling, and whether Marvell accepts them within its stated remedy ceiling.
- US review. A second request from the FTC or DOJ would extend the timetable substantially. None has been reported.
- EU and other filings. Pre-notification can take months. Phase II would add significant time.
- Shareholder votes. Required at both companies and the near-term hurdle.
- Geopolitics and export policy. Reported FCC consideration of adding optical transceivers to the Covered List is a separate risk, disclosed in Lumentum's 10-Q as not yet finalised. [Source: Lumentum 10-Q risk factors, Q1 FY2027]
Effect on the company and deal value
Approval (conditional or unconditional): The base case is closing in the first half of 2028 or later, with remedies that may trim bundling or force third-party supply commitments. Remedies could affect the combined business as much as the approval decision.
Delay: A SAMR or second-request delay of a few months would not by itself breach the outside date, because the H1 2028 target sits inside the extended window. Delay extends the period in which LITE holders carry MRVL price risk and customers may dual-source away from Marvell DSPs.
Rejection or legal block: Marvell owes Lumentum $3.2 billion, roughly 2.8% of implied EV, and the companies revert to standalone paths. Lumentum would keep its own module unit and laser franchise, but the strategic premium disappears.
Deal value is a moving target. The exchange ratio is fixed, so value per LITE share moves one-for-one with MRVL, scaled by 4.5. Each $1 change in MRVL changes the implied value by $4.50 per LITE share.
- MRVL closed at , down on Nov 13.
- 4.5 × $156.76 gives an implied value of per LITE share, the $1,132 headline. [Calculation]
- LITE closed at , down on the day. The gross spread to the implied value is . [Calculation] The spread combines time value and failure risk, and the two cannot be separated from this data.
Judgment. A regulatory block is a real tail risk, but the evidence points to a long review that ends in conditional approval. The larger near-term driver of LITE holder value is the MRVL share price and the timing of SAMR. Watch for a second request, a formal SAMR acceptance or pull-and-refile, an EU Phase II notice, and any public list of required approvals. A narrowing spread after a clear SAMR path would lower implied failure risk. A widening spread or a later closing window would raise it.
Sources
- Lumentum Form 8-K, filed Nov 2, 2026 (event date Nov 1): https://www.sec.gov/Archives/edgar/data/1633978/000119312526442758/d163169d8k.htm
- Marvell press release, Nov 2, 2026: https://investor.marvell.com/news-events/press-releases/detail/1040/marvell-and-lumentum-to-combine-creating-a-category-leader-in-ai-connectivity
- Lumentum Form 425 summary (StockTitan), Nov 9, 2026: https://www.stocktitan.net/sec-filings/LITE/425-lumentum-holdings-inc-business-combination-communication-231b8010b4ea.html
- Lumentum 10-Q Item 1A (FilingSpy), period ended Sep 26, 2026: https://filingspy.com/securities/s-3321/filings/0001628280-26-069615/II/item_1a
- Briefs, "Marvell's $115B Lumentum Bid Faces Market Doubt," Nov 10, 2026: https://www.briefs.co/news/marvell-s-115-billion-lumentum-bid-meets-a-cautious-market/
- btw.media, "Marvell–Lumentum deal sets a $3.2bn regulatory failure fee," Nov 3, 2026: https://btw.media/en/marvell-lumentum-regulatory-termination-fee
- Driven research note on the Marvell–Lumentum review (secondary synthesis; cites Bloomberg Nov 9, All Mergers, Counterpoint, Global Business Digest, Fusion42, Dombey Capital): https://driven.ai/share/qk79o29okzehg6jbg08cguqj
- Global Business Digest, Nov 5, 2026 (secondary): https://globalbusinessdigest.com/marvell-lumentum-deal-ai-optical-antitrust/
- Counterpoint Research, Nov 3, 2026: https://counterpointresearch.com/en/insights/marvells-dollar-115b-lumentum-deal-climbs-the-ai-laser-wall-to-take-on-broadcom
- Market quotes, LITE and MRVL, Nov 13, 2026 close (16:00 ET), via Driven market data